| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 09/26/2002 | US20020137740 CRF (corticotropin releasing factor) antagonists; 4-(2-Chloro-4-methoxyphenyl)-5-methyl-2-(N-(5-ethoxy-carbonyl-2 -methoxyphenyl)-N-propylamino)thiazole for example |
| 09/26/2002 | US20020137689 Hypolipidemic agents |
| 09/26/2002 | CA2441564A1 Production of pancreatic islet cells and delivery of insulin |
| 09/26/2002 | CA2441563A1 Allosteric adenosine receptor modulators |
| 09/26/2002 | CA2441388A1 Modified insulin with reduced immunogenicity |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/25/2002 | EP1243581A1 Pyridinium compounds useful for the treatment of AGE-related diseases |
| 09/25/2002 | EP1243275A1 Insulin-containing medicament for peroral application and method for the production thereof |
| 09/25/2002 | EP1242617A2 Method of classifying a thyroid carcinoma using differential gene expression |
| 09/25/2002 | EP1242583A2 Human oxidoreductase proteins |
| 09/25/2002 | EP1242445A1 14,15-cyclopropanosteroids of the 19-norandrostane series, method for producing said compounds and pharmaceutical preparation containing said compounds |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242121A2 Polypeptide compositions with improved stability |
| 09/25/2002 | EP1242094A1 Methods for treating mild cognitive impairment |
| 09/25/2002 | EP1242012A1 Improved transdermal contraceptive delivery system and process |
| 09/25/2002 | EP1241935A2 Methods for producing transgenic animals |
| 09/25/2002 | EP1070059B1 Chromanone and thiochromanone derivatives |
| 09/25/2002 | CN1371388A Hexapeptide with stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation differentiation and apoptosis |
| 09/25/2002 | CN1371376A Substituted purin derivatives as inhibitors of cell adhesion |
| 09/25/2002 | CN1371365A Piperidine alcohols |
| 09/25/2002 | CN1370526A Treating method of nuclear factor-KB mediated diseases and dysfuction |
| 09/24/2002 | US6455582 Treating cancer |
| 09/24/2002 | US6455572 Estrogen agonist/antagonist metabolites |
| 09/24/2002 | US6455517 For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated |
| 09/24/2002 | US6455502 Compounds and compositions as protease inhibitors |
| 09/24/2002 | US6455077 Solvent extraction of herbs |
| 09/24/2002 | US6455049 Biologically active and particularly peptide molecules having a potentiating effect on growth hormone biological activity |
| 09/24/2002 | US6455044 5c8 antigen |
| 09/20/2002 | WO2001070704A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/20/2002 | CA2403732A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/19/2002 | WO2002072832A2 Therapeutic binding molecules |
| 09/19/2002 | WO2002072780A2 Igf antagonist peptides |
| 09/19/2002 | WO2002072626A2 Novel form of the phgpx protein as a diagnostic marker for male infertility |
| 09/19/2002 | WO2002072602A2 Somatostatin antagonists |
| 09/19/2002 | WO2002072561A1 Piperazinyltriazines as estrogen receptor modulators |
| 09/19/2002 | WO2002072106A2 Combined method for treating hormono-dependent disorders with exemestane |
| 09/19/2002 | WO2002072084A2 Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity |
| 09/19/2002 | WO2002072078A2 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 09/19/2002 | WO2002072034A2 Chronotherapeutic dosage forms |
| 09/19/2002 | WO2002072033A2 Chronotherapeutic dosage forms containing glucocorticosteroid |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002055532A3 Variant growth hormone molecules conjugated with macromolecular compounds |
| 09/19/2002 | WO2002050028A3 Substituted benzoindoles as spla2 inhibitors |
| 09/19/2002 | WO2002030876A3 Cyclic carboxylic acids as integrin antagonists |
| 09/19/2002 | WO2002018553A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2001016139A9 Androgen receptor modulator compounds and methods |
| 09/19/2002 | US20020132973 Peptide parathyroid hormone analogs |
| 09/19/2002 | US20020132844 Substituted pyrazole compounds useful for the treatment of mammalian infertility. |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132820 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 09/19/2002 | US20020132816 Estrogen agonists/antagonists for preventing breast cancer |
| 09/19/2002 | US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. |
| 09/19/2002 | US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration |
| 09/19/2002 | US20020131988 Provides flexibility in adjusting release of medicament; faster onset of release can be provided along with a long-term sustained-release |
| 09/19/2002 | DE10112151A1 New 5-(4-(indolyl-alkyl)-piperazino)-benzofuran-2-carboxamides useful e.g. for treating depression, anxiety, psychiatric or cerebral disorders or pain, are 5-HT-1A receptor agonists and 5-HT reuptake inhibitors |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2458451A1 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 09/19/2002 | CA2440641A1 Chronotherapeutic dosage forms containing glucocorticosteroid |
| 09/19/2002 | CA2439735A1 Igf antagonist peptides |
| 09/19/2002 | CA2439498A1 Somatostatin antagonists |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2437963A1 Therapeutic binding molecules |
| 09/19/2002 | CA2434611A1 Combined method for treating hormono-dependent disorders |
| 09/18/2002 | EP1241167A1 3-ethyl-, 3-propyl- or 3-butyl-chroman and -thiochroman derivatives |
| 09/18/2002 | EP1241166A1 3-methyl-chroman and -thiochroman derivatives |
| 09/18/2002 | EP1241165A1 Optically active chroman and thiochroman derivatives |
| 09/18/2002 | EP1241158A1 Compound having hydroxycarbonyl-halogenoalkyl side chain |
| 09/18/2002 | EP1240335A2 Proteases |
| 09/18/2002 | EP1240196A2 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 09/18/2002 | EP1240156A1 3-methyl-chromane or thiochromane derivatives |
| 09/18/2002 | EP1240155A1 Metal salts of 3-methyl-chromane or thiochromane derivatives |
| 09/18/2002 | EP1239871A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 09/18/2002 | EP1239854A1 Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 09/18/2002 | EP1239829A1 Devices for the delivery of drugs having antiprogestinic properties |
| 09/18/2002 | EP0757681B1 CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS |
| 09/18/2002 | EP0575357B1 Human follicle stimulating hormone receptor |
| 09/18/2002 | CN1370154A Aminothiazole derivatives and their use as CRF receptor ligands |
| 09/18/2002 | CN1370072A Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 09/18/2002 | CN1370069A Use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes |
| 09/18/2002 | CN1370068A Pharmaceutical agent comprising benzamide derivative as active ingredient |
| 09/17/2002 | US6452032 Organosilyl compounds having nuclear hormone receptor modulating activity |
| 09/17/2002 | US6451994 Polypeptides, polynucleotides; drug screening; diagnosing alzheimer*s, parkinson*s, huntington*s, and creutzfelt-jacob disease; amyotrophic lateral sclerosis, cystic fibrosis |
| 09/17/2002 | US6451849 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol |
| 09/17/2002 | US6451839 Indole sPLA2 inhibitors |
| 09/17/2002 | US6451783 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 09/17/2002 | US6451782 Use of 4-androstene-3alpha,17 beta-diol to increase testosterone levels in humans |
| 09/17/2002 | US6451561 Growth hormone variants |
| 09/17/2002 | US6451347 Complexing oxidized or deamidated human growth hormone with metal; precipitation, isolation |
| 09/17/2002 | US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8 |
| 09/17/2002 | CA2057338C Diarylfluoromethane compounds |
| 09/12/2002 | WO2002070706A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | WO2002070669A2 Secreted proteins |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |